NEWARK, N.J.--(BUSINESS WIRE)--Symbiomix Therapeutics, a late-stage, privately held, biopharmaceutical company with a focus on women’s health, today made its first corporate announcement. The company reported completion of enrollment in a Phase 2 clinical trial evaluating the company’s lead product, SYM-1219, as the first oral, single dose treatment for bacterial vaginosis (BV) in the US.
Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs. Symbiomix is backed by three of the world’s leading healthcare venture capital firms: OrbiMed, Fidelity Biosciences and HBM Partners, and by financial services partner Square 1 Bank. The Company’s lead product is SYM-1219 (secnidazole), a next generation 5-nitroimidazole antibiotic. It is a New Chemical Entity (NCE) to the United States.
Help employers find you! Check out all the jobs and post your resume.
